Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Female Sexual Dysfunction: Lead Agents Are New Formulations Of Marketed Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Procter & Gamble will likely have the first product to treat hypoactive sexual desire disorder in women with its Phase III testosterone patch Intrinsa. Vivus has late-stage compounds for two major components of female sexual dysfunction: a testosterone spray for hypoactive desire and a topical alprostadil for female sexual arousal disorder.

You may also be interested in...



P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005

NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.

P&G's Intrinsa Priority Review Puts Approval Timeline At Early 2005

NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.

BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails

Company aims to capture 10%-20% of the testosterone gel market with Bio-T-Gel. Female sexual dysfunction will be next frontier for BioSante gels, with Procter & Gamble as trailblazer in FSD market, BioSante CEO says.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel